Need help or have questions about your order? Call 510-991-8265Questions about your order? Call 510-991-8265

Sign InShop GLPs
Shop GLPs

Testosterone Enanthate Real-World Response Rate: What Clinical Data and Patient Reports Actually Show

By
Published Updated Last reviewed
9 linked public sourcesEditorial, sourcing, and corrections policy

At a glance

  • Approved use / Primary or hypogonadotropic hypogonadism; age-related hypogonadism not established [1]
  • Label dose / 50 to 400 mg intramuscularly every 2 to 4 weeks [1]
  • Symptom trial / 790 men aged 65 or older, testosterone gel vs placebo gel, 1 year [2]
  • Pooled body composition / Total fat down 1.6 kg, fat-free mass up 1.6 kg with testosterone, 29 trials [5]
  • Hematocrit / Intramuscular enanthate/cypionate raised mean hematocrit 4.0% vs placebo [3]
  • Cardiovascular / TRAVERSE MACE 7.0% with gel vs 7.3% with placebo; blood pressure rises class-wide [6][4]

Does Testosterone Enanthate Have a Response Rate?

A response rate needs a defined outcome, a counted group and a time point. The enanthate label gives the indication, a dose range of 50 to 400 mg every 2 to 4 weeks, and a list of adverse reactions, but no responder percentage [1]. The symptom trial described below used testosterone gel. A separate phase II study combined testosterone cypionate/enanthate with olaparib, alongside ongoing androgen deprivation, in men with metastatic castration-resistant prostate cancer and reported a 31% PSA50 response rate at 12 weeks; that result does not establish a response rate for testosterone enanthate replacement therapy [7].

What the Symptom Data Show

A randomized trial assigned 790 men aged 65 or older with serum testosterone below 275 ng/dL to testosterone gel or placebo gel for 1 year [2]. Sexual activity, desire and erectile function improved; vitality did not. Walking distance was mixed: the Physical Function Trial alone found no significant difference, but an analysis across all three trials did, with 20.5% of testosterone-treated men versus 12.6% of placebo-treated men improving by at least 50 meters (P=0.003) [2].

A separate meta-analysis of 29 randomized trials (1,083 middle-aged and older men), not specific to testosterone enanthate, found a 1.6-kg reduction in total body fat and a 1.6-kg increase in fat-free mass with testosterone treatment, with no change in body weight [5].

Hematocrit, Blood Pressure and Heart Risk

Hematocrit is the outcome most clearly tied to formulation. Across 29 placebo-controlled trials and 3,393 men, intramuscular enanthate/cypionate raised mean hematocrit by 4.0% (95% CI 2.9 to 5.1) versus placebo; gel raised it 3.0% (95% CI 1.8 to 4.3) [3]. A retrospective review of 178 men found hematocrit above 50% in 66.7% of men on injectable testosterone versus 12.8% on gels, though that study was not randomized and the injection group was younger with higher baseline hematocrit [8]. The enanthate label lists polycythemia among adverse reactions [1].

FDA's February 2025 labeling action states that ambulatory blood pressure studies confirmed a blood pressure increase with all testosterone products, class-wide [4]. The enanthate label says testosterone can increase blood pressure, that blood pressure should be monitored periodically, and that testosterone products are not recommended in uncontrolled hypertension [1].

TRAVERSE, which tested a gel and not injections, randomized 5,246 men aged 45 to 80 with hypogonadism and high cardiovascular risk to daily 1.62% testosterone gel or placebo gel: major adverse cardiovascular events occurred in 7.0% versus 7.3%, hazard ratio 0.96 (95% CI 0.78 to 1.17), meeting noninferiority [6]. The enanthate label still says long-term cardiovascular safety trials have not been conducted and that some studies, but not all, reported an increased MACE risk [1].

Frequently asked questions

What dose does the enanthate label recommend?
For male hypogonadism, 50 to 400 mg intramuscularly every 2 to 4 weeks; total doses above 400 mg per month are not required, and injections more often than every 2 weeks are rarely indicated [1].
What did the largest symptom trial find?
In 790 men aged 65 or older, 1 year of testosterone gel improved sexual activity, desire and erectile function, did not improve vitality, and gave mixed walking-distance results [2].
Does testosterone enanthate raise hematocrit?
Intramuscular enanthate/cypionate raised mean hematocrit by 4.0% versus placebo across 29 trials, and the enanthate label lists polycythemia among adverse reactions [3][1].
Is testosterone enanthate safe for the heart?
TRAVERSE found noninferiority for major cardiovascular events with testosterone gel, 7.0% versus 7.3% [6]. FDA says blood pressure increases were confirmed with all testosterone products [4], and the enanthate label says testosterone can raise blood pressure and is not recommended in uncontrolled hypertension [1].
Can testosterone enanthate affect fertility?
Testosterone treatment can suppress sperm production; the enanthate label says oligospermia may occur at high doses. In a retrospective study of 66 men with infertility after testosterone use, 70% reached a total motile count above 5 million within 12 months after stopping testosterone and receiving hCG plus a selective estrogen receptor modulator. The study did not establish a result specific to testosterone enanthate [1][9].

References

  1. U.S. National Library of Medicine, DailyMed. Testosterone enanthate injection USP intramuscular, Hikma prescribing information. Testosterone enanthate injection USP intramuscular, Hikma label
  2. Snyder PJ, Bhasin S, Cunningham GR, Matsumoto AM, Stephens-Shields AJ, Cauley JA, et al. Effects of Testosterone Treatment in Older Men. N Engl J Med. 2016;374(7):611-24. Effects of Testosterone Treatment in Older Men
  3. Nackeeran S, Kohn T, Gonzalez D, White J, Ory J, Ramasamy R. The Effect of Route of Testosterone on Changes in Hematocrit: A Systematic Review and Bayesian Network Meta-Analysis of Randomized Trials. J Urol. 2022;207(1):44-51. The Effect of Route of Testosterone on Changes in Hematocrit: A Systematic Review and Bayesian Network Meta-Analysis of Randomized Trials
  4. FDA issues class-wide labeling changes for testosterone products | FDA. FDA issues class-wide labeling changes for testosterone products | FDA
  5. Isidori AM, Giannetta E, Greco EA, Gianfrilli D, Bonifacio V, Isidori A, et al. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. Clin Endocrinol (Oxf). 2005;63(3):280-93. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis
  6. Lincoff AM, Bhasin S, Flevaris P, Mitchell LM, Basaria S, Boden WE, et al. Cardiovascular Safety of Testosterone-Replacement Therapy. N Engl J Med. 2023;389(2):107-117. Cardiovascular Safety of Testosterone-Replacement Therapy
  7. Schweizer MT, Gulati R, Yezefski T, Cheng HH, Mostaghel E, Haffner MC, et al. Bipolar androgen therapy plus olaparib in men with metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2023;26(1):194-200. Bipolar androgen therapy plus olaparib in men with metastatic castration-resistant prostate cancer
  8. Pastuszak AW, Gomez LP, Scovell JM, Khera M, Lamb DJ, Lipshultz LI. Comparison of the Effects of Testosterone Gels, Injections, and Pellets on Serum Hormones, Erythrocytosis, Lipids, and Prostate-Specific Antigen. Sex Med. 2015;3(3):165-73. Comparison of the Effects of Testosterone Gels, Injections, and Pellets on Serum Hormones, Erythrocytosis, Lipids, and Prostate-Specific Antigen
  9. Kohn TP, Louis MR, Pickett SM, Lindgren MC, Kohn JR, Pastuszak AW, et al. Age and duration of testosterone therapy predict time to return of sperm count after human chorionic gonadotropin therapy. Fertil Steril. 2017;107(2):351-357.e1. Age and duration of testosterone therapy predict time to return of sperm count after human chorionic gonadotropin therapy
Evidence overview for Testosterone Enanthate Real-World Response Rate: What Clinical Data and Patient Reports Actually Show